{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=34",
    "query": {
      "intervention": "cohort 4",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:40:17.259Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02659644",
      "title": "A Study of Oral L-citrulline in Sickle Cell Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Oral L-citrulline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2018-06-21",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02659644"
    },
    {
      "nct_id": "NCT04382885",
      "title": "Cariprazine Pediatric ASD PK Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Cariprazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-06-26",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-12",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 3,
      "location_summary": "Orange, California • Atlanta, Georgia • Decatur, Georgia",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04382885"
    },
    {
      "nct_id": "NCT02537691",
      "title": "Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FP",
          "type": "DRUG"
        },
        {
          "name": "LABA",
          "type": "DRUG"
        },
        {
          "name": "LTRA",
          "type": "DRUG"
        },
        {
          "name": "LAMA",
          "type": "DRUG"
        },
        {
          "name": "Theophylline",
          "type": "DRUG"
        },
        {
          "name": "Oral Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 483,
      "start_date": "2015-08-28",
      "completion_date": "2017-07-10",
      "has_results": false,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02537691"
    },
    {
      "nct_id": "NCT00074490",
      "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia",
        "Myeloproliferative Disorders",
        "Multiple Myleoma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell (PBSC) transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells",
          "type": "GENETIC"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic hematopoietic stem cell transplant (HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "11 Years to 90 Years"
      },
      "enrollment_count": 442,
      "start_date": "2004-01-01",
      "completion_date": "2017-08-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-31",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074490"
    },
    {
      "nct_id": "NCT00784823",
      "title": "Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bortezomib 1 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib 1.3 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib 1.6 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 32,
      "start_date": "2007-01",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-11",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784823"
    },
    {
      "nct_id": "NCT07757802",
      "title": "Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "DV901-NP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DV902-NP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505 TF mRNA-gp160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505 w24 mRNA-gp160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACU-026-001-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2026-12-01",
      "completion_date": "2028-10-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07757802"
    },
    {
      "nct_id": "NCT01074372",
      "title": "Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "REGN727",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-03",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074372"
    },
    {
      "nct_id": "NCT03220295",
      "title": "Putative Cognitive Enhancer VU319",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Single Dose of VU319",
          "type": "DRUG"
        },
        {
          "name": "Single Dose Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fed State",
          "type": "OTHER"
        },
        {
          "name": "Fasted State",
          "type": "OTHER"
        },
        {
          "name": "Dose Escalation of VU319",
          "type": "DRUG"
        },
        {
          "name": "Placebo Dose Escalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2017-07-28",
      "completion_date": "2019-10-30",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220295"
    },
    {
      "nct_id": "NCT05492500",
      "title": "A Study of Ponsegromab in People With Heart Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Main cohort (Cohort A): Ponsegromab low dose",
          "type": "DRUG"
        },
        {
          "name": "Main cohort (Cohort A): Ponsegromab medium dose",
          "type": "DRUG"
        },
        {
          "name": "Main cohort (Cohort A): ponsegromab high dose",
          "type": "DRUG"
        },
        {
          "name": "Main cohort (Cohort A): Matched placebo",
          "type": "OTHER"
        },
        {
          "name": "Open-label, PK Cohort (Cohort B): ponsegromab low dose",
          "type": "DRUG"
        },
        {
          "name": "Open-label, PK Cohort (Cohort B): ponsegromab medium dose",
          "type": "DRUG"
        },
        {
          "name": "Open-label, PK Cohort (Cohort B): ponsegromab high dose",
          "type": "DRUG"
        },
        {
          "name": "Optional Cohort C: Ponsegromab low dose",
          "type": "DRUG"
        },
        {
          "name": "Optional Cohort C: Matched placebo",
          "type": "OTHER"
        },
        {
          "name": "Optional Cohort D: Ponsegromab high dose",
          "type": "DRUG"
        },
        {
          "name": "Optional Cohort D: Matched placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 455,
      "start_date": "2022-09-26",
      "completion_date": "2025-03-05",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 22,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hazel Crest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05492500"
    },
    {
      "nct_id": "NCT04144036",
      "title": "Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Neihulizumab, 3 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Neihulizumab, 6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neihulizumab, 9 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neihulizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sameem M. Abedin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-12-14",
      "completion_date": "2024-07-07",
      "has_results": false,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-11-19T05:40:17.259Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04144036"
    }
  ]
}